Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

Publication date: Sep 05, 2019

The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo in participants with RMS. The secondary objectives of the study are to evaluate the effects of BIIB061 versus placebo on brain magnetic resonance imaging (MRI) markers of remyelination and axon preservation in chronic Multiple Sclerosis lesions and to evaluate the effects of BIIB061 versus placebo on additional measures of improved disability outcome.

Concepts Keywords
Allergy Viral hepatitis
Antibody Multiple sclerosis
Antigen RTT
Avonex Hepatitis
Axon Interferon beta-1a
Biogen Healthcare-associated infections
Blockade Immunology
Brain Cytokines
Claustrophobia Medicine
Dental Braces Medical specialties
Depression Vaccination
Disability HCV
ECG Natural infection
Gadolinium Clinically severe depression
Gastrectomy Multiple Sclerosis RMS
HBsAg History systemic hypersensitivity
HCV Disease
Hepatitis Multiple Sclerosis
Hypersensitivity Reaction Metal devices
Immunity Magnetic resonance imaging
Immunodeficiency MRI
Infection
Interferon
Magnetic Resonance Imaging
MRI
Multiple Sclerosis
Neurologist
Pacemakers
Pharmacological
Placebo
Progressive
Protocol
Rebif
Receptors
Renal Impairment
RNA
Spinal Cord
Suicidal Ideation
Vaccination
Virus

Semantics

Type Source Name
gene UNIPROT ALG3
gene UNIPROT NR4A2
disease MESH abnormalities
disease MESH depression
disease MESH suicidal ideation
disease MESH infection
pathway BSID Hepatitis B
pathway BSID Hepatitis C
disease DOID hepatitis B infection
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
disease MESH hepatitis B
disease DOID hepatitis C infection
disease MESH hepatitis C
disease MESH claustrophobia
disease MESH renal
disease MESH allergy
disease DOID allergy
disease MESH Contraindications
drug DRUGBANK Interferon beta-1a
drug DRUGBANK Gadolinium
disease MESH relapse
disease DOID secondary progressive multiple sclerosis
disease DOID relapsing-remitting multiple sclerosis
disease MESH secondary progressive multiple sclerosis
disease MESH relapsing-remitting multiple sclerosis
gene UNIPROT CYREN
disease MESH Multiple Sclerosis
disease DOID Multiple Sclerosis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *